Sun Pharmaceutical Industries appoints Dheeraj Sinha as Executive Vice President, Chief Information Officer

Written by Ruchika Sharma Published On 2024-04-04T11:30:24+05:30 | Updated On 4 April 2024 9:17 PM IST

Sun Pharmaceutical Industries appoints Dheeraj Sinha as Executive Vice President, Chief Information Officer

Mumbai: Sun Pharmaceutical Industries Limited has appointed Dheeraj Sinha as Executive Vice President and Chief Information Officer effective from April 3, 2024.

Sinha replaces Anil Rao, Senior Vice President and Chief Information Officer. Anil Rao resigned due to personal reasons and his last working day with the Company will be April 30, 2024.

"This is to inform that Mr. Dheeraj Sinha is appointed as Executive Vice President and Chief Information Officer effective from April 3, 2024," the Company stated in a BSE filing.

Dheeraj Sinha was associated with JSW as EVP & Group Chief Information Officer for 8+ years. In a career spanning over three decades, he has been associated with JSW Group, Apollo Tyres, Infovergix Technologies, UMIT Ltd. and Modi Xerox. Prior to JSW, he was the Group CIO and Global Supply Chain Head with Apollo Tyres for over 12 years,

Sinha is MBA in Finance & Operations from MDI and B.Tech. in Electronics and Communication Engineering from Birla Institute of Technology, Mesra and has undergone Strategic Leadership Programs from Brown University and IMD Laussane, Switzerland. Also, he is currently pursuing his Ph.D. from Narsee Monjee University, Mumbai.

Read also: Sun Pharma to buy 16.33 percent stake in Surgimatix for over Rs 25 crore

Medical Dialogues had earlier reported the retirement of Sailesh Trambaklal Desai from Sun Pharma's Board of Directors, as he completed his term as a Director on March 31, 2024.

Read also: Sailesh T Desai retires from Sun Pharma Board of Directors

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

sun pharmasun pharma newsDheeraj SinhaappointmentAnil Rao

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751